Ambassador Gabriela Shalev is Israel’s fourteenth Permanent Representative to the United Nations. In July, 2008, she became the first woman appointed to this prestigious post.
Like many other famous Israeli diplomats and government officials, Ambassador Shalev is a Hebrew University alumna. She graduated suma cum laude upon earning her Bachelors, Masters and Doctoral degrees within the Faculty of Law.
Previously, Ambassador Shalev served as President of the Academic Council and Rector of Ono Academic College in Israel. Until her early retirement in 2002, she was a full professor of contract law at The Hebrew University of Jerusalem and has taught contract law and comparative law in universities across the United States, Europe, and Canada. She is a leading expert in Israel in the fields of contract law and procurement contracts. Ambassador. Shalev has provided legal advice and wrote legal opinions for public institutions, arbitrators, and lawyers, in Israel and around the world.
Ambassador Shalev was the Chief Legal Editor of the Judgments of the Supreme Court of Israel and legal editor of the Hebrew Encyclopedia. She has earned numerous awards for academic legal research, including the Sussman Prize for Law (1989), the Zeltner Prize for Law (1991), and the Israel Bar Association Prize (2003). She has written nine books and over one hundred articles in Hebrew and in English, mostly on contract law. Ambassador Shalev recently published her latest book Contract Law – General Part, Towards Codification of the Civil Law, which is an updated version of her works on contract law in Israel. Ambassador Shalev’s contract law textbook is the standard textbook used in law schools and law offices throughout Israel.
In addition to her academic achievements, Ambassador Shalev has substantial experience in the public and private sector. Prior to her appointment, she served as chairperson of the audit committees of Bank Hapo’alim and the Israel Electric Company, as well as on the boards of Ma’ariv; the Hadassah Medical Organization, Fibi Holdings Co.; Koor Industries; Osem Investments; Teva Pharmaceutical Industries Ltd.; and Delek Ltd. Group.